Navigation Links
Study finds potential key to immune suppression in cancer
Date:1/19/2012

TAMPA, Fla. In a study investigating immune response in cancer, researchers from Moffitt Cancer Center in Tampa, Fla., and the University of South Florida have found that interaction between the immune system's antigen-specific CD4 T cells and myeloid-derived suppressor cells (MDSC) cells that play a major role in cancer-related immune suppression dramatically change the nature of MDSC-mediated suppression. By contrast, the same effect was not observed when MDSCs interacted with the immune system's CD8 T cells.

Their study appeared in a recent issue of Cancer Research, published by the American Association for Cancer Research.

According to the authors, it has been established that inadequate immune response in cancer is a critical element in tumor escape, and that myeloid-derived suppressor cells (MDSCs) cells that which normally keep the immune system in check and prevent it from attacking otherwise healthy tissue can suppress the anti-tumor response and play a major role in tumor associated immune abnormalities.

In addition, research has shown that MDSCs block other immune system cells (such as CD 8 "killer" T cells) from binding with proteins that identify foreign antigens on the surface of unhealthy cancer cells and, in doing so, mark them as targets.

"To better understand the biology of immune defects in cancer, our study investigated the antigen-specific nature of MDSCs and their ability to cause antigen specific CD4 T cell tolerance," said study corresponding author Dmitry Gabrilovich, M.D., Ph.D., who holds the Robert Rothman Endowed Chair in Cancer Research at Moffitt and whose research focus is on immunology. "We found that antigen specific CD4 T cells were able to dramatically enhance the immune suppressive activity of MDSC by converting them into powerful non-specific suppressors. But, to our surprise, we did not see the same response from CD8 T cells."

The researchers initially investigated several tumors modeled in mice but focused on two models of particular interest.

They reported that major histocompatability complex (MHC) class II molecules found only on a few specialized cell types played a role in this conversion to MDSC-mediated suppression when MHC class II and MDSC "cross-linked" through cell-to-cell contact. The effect, however, was dependent on the expression of MHC class II.

"This study showed for the first time that activated antigen-specific T-cells can potentiate the immune suppressive activity of MDSC by converting these cells to non-specific suppressors and, thus, limit the ability of the host to mount a potent immune response," concluded the authors.

The researchers suggested that their study might shed light on a mechanism that may act as a "negative feedback loop" aimed at controlling immune responses that become "dysregulated" in cancer.


'/>"/>
Contact: Ferdie De Vega
Ferdinand.DeVega@moffitt.org
813-745-7858
H. Lee Moffitt Cancer Center & Research Institute
Source:Eurekalert

Related medicine news :

1. Despite Treatment, Employees with Depression Generate Higher Absentee Costs, According to Thomson Reuters Study
2. American Council on Exercise (ACE) Study Reveals Kettlebells Provide Powerful Workout in Short Amount of Time
3. TV drama can be more persuasive than news program, study finds
4. Study carried out into biological risks of eating reptiles
5. Neuroimaging study may pave way for effective Alzheimers treatments
6. Study finds racial gaps continue in heart disease awareness
7. Luth Researchs IndicatorEDG(TM) Study Finds Americans Hopes of Achieving Their Dreams Are Fading
8. First blinded study of venous insufficiency prevalence in MS shows promising results
9. Soothing infants with food focus of childhood obesity study
10. People with anxiety disorder less able to regulate response to negative emotions, study shows
11. American Heart Association Rapid Access Journal Report: Study Finds Racial Gaps Continue in Heart Disease Awareness, Low Knowledge of Heart Attack Warning Signs Among Women
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2017)... ... 25, 2017 , ... ProRehab Physical Therapy (PRPT) ... physical therapy provider for Derby City CrossFit, effective immediately. , In addition to ... and effectively as possible, ProRehab’s sports physical therapists will work with athletes to ...
(Date:4/25/2017)... ... April 25, 2017 , ... A recent report ... score performance for the 2015-16 school year across Wisconsin’s public schools, charter schools, ... highlights important patterns in student test score performance, the report’s limited analyses fail ...
(Date:4/25/2017)... ... April 25, 2017 , ... As pharmaceutical companies are ... help with process innovation in drug formulation and manufacturing. CoreRx offers its ... analytical equipment in support of their development and manufacturing goals. , The ...
(Date:4/25/2017)... , ... April 25, 2017 , ... Saad B. Chaudhary, MD is committed to providing ... acute or chronic problems, I focus on preventative care with all my patients to alleviate ... any questions, always feel free to contact my office and my trained staff will assist ...
(Date:4/25/2017)... ... 2017 , ... Vetoquinol USA® , a world-class developer ... of the EQUISTRO line, at this week’s Rolex Kentucky Three-Day Event in Lexington. ... level. , The scientifically-developed Flexadin UCII supports the body’s normal repair of cartilage ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... Research and Markets has announced ... Market Prospects: Addressing Production Complexities Through Risk Management and ... ... Pipeline and Market Prospects: Overcoming Production Complexities Through Risk ... of the current trends in the global biosimilars market, ...
(Date:4/20/2017)... , April 20, 2017 Research and ... Technologies - Innovation Driven by Rapidly Expanding Injectables Market and Increasing ... their offering. ... for drug delivery technologies will rise from USD 20 Billion in ... Global Drug Delivery Technologies - Innovation Driven by Rapidly Expanding ...
(Date:4/20/2017)... --  ZappRx, Inc ., a digital health company focused on ... it closed $25 million in Series B funding led by ... Seattle that is part of a ... B round included participation from SR One , who ... (formerly Google Ventures). As part of the financing, ...
Breaking Medicine Technology: